These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 24262194)

  • 21. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease.
    El-Agnaf OM; Salem SA; Paleologou KE; Curran MD; Gibson MJ; Court JA; Schlossmacher MG; Allsop D
    FASEB J; 2006 Mar; 20(3):419-25. PubMed ID: 16507759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSF α-synuclein as a diagnostic biomarker for Parkinson disease and related dementias.
    Ballard CG; Jones EL
    Neurology; 2010 Nov; 75(20):1760-1. PubMed ID: 20962288
    [No Abstract]   [Full Text] [Related]  

  • 23. Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis.
    Eusebi P; Giannandrea D; Biscetti L; Abraha I; Chiasserini D; Orso M; Calabresi P; Parnetti L
    BMJ Open; 2016 Jun; 6(6):e011113. PubMed ID: 27297011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's disease.
    Russo MJ; Orru CD; Concha-Marambio L; Giaisi S; Groveman BR; Farris CM; Holguin B; Hughson AG; LaFontant DE; Caspell-Garcia C; Coffey CS; Mollon J; Hutten SJ; Merchant K; Heym RG; Soto C; Caughey B; Kang UJ
    Acta Neuropathol Commun; 2021 Nov; 9(1):179. PubMed ID: 34742348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic biomarkers for Parkinson's disease: focus on α-synuclein in cerebrospinal fluid.
    Kalia LV
    Parkinsonism Relat Disord; 2019 Feb; 59():21-25. PubMed ID: 30466800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies.
    Singer W; Schmeichel AM; Shahnawaz M; Schmelzer JD; Boeve BF; Sletten DM; Gehrking TL; Gehrking JA; Olson AD; Savica R; Suarez MD; Soto C; Low PA
    Ann Neurol; 2020 Sep; 88(3):503-512. PubMed ID: 32557811
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.
    Mollenhauer B; Trautmann E; Taylor P; Manninger P; Sixel-Döring F; Ebentheuer J; Trenkwalder C; Schlossmacher MG
    Neurosci Lett; 2013 Jan; 532():44-8. PubMed ID: 23149132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.
    del Campo M; Mollenhauer B; Bertolotto A; Engelborghs S; Hampel H; Simonsen AH; Kapaki E; Kruse N; Le Bastard N; Lehmann S; Molinuevo JL; Parnetti L; Perret-Liaudet A; Sáez-Valero J; Saka E; Urbani A; Vanmechelen E; Verbeek M; Visser PJ; Teunissen C
    Biomark Med; 2012 Aug; 6(4):419-30. PubMed ID: 22917144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms.
    Winkel I; Ermann N; Żelwetro A; Sambor B; Mroczko B; Kornhuber J; Paradowski B; Lewczuk P
    J Neural Transm (Vienna); 2021 Jun; 128(6):817-825. PubMed ID: 34036433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cerebrospinal fluid biomarkers for the early diagnosis of Parkinson's disease].
    da Costa AG; Gago MF; Garrett C
    Acta Med Port; 2011 Dec; 24 Suppl 4():761-8. PubMed ID: 22863482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    Mollenhauer B; Bowman FD; Drake D; Duong J; Blennow K; El-Agnaf O; Shaw LM; Masucci J; Taylor P; Umek RM; Dunty JM; Smith CL; Stoops E; Vanderstichele H; Schmid AW; Moniatte M; Zhang J; Kruse N; Lashuel HA; Teunissen C; Schubert T; Dave KD; Hutten SJ; Zetterberg H
    J Neurochem; 2019 Apr; 149(1):126-138. PubMed ID: 30125936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
    Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
    Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
    Førland MG; Öhrfelt A; Dalen I; Tysnes OB; Blennow K; Zetterberg H; Pedersen KF; Alves G; Lange J
    Parkinsonism Relat Disord; 2018 Apr; 49():4-8. PubMed ID: 29409704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease.
    Tokuda T; Salem SA; Allsop D; Mizuno T; Nakagawa M; Qureshi MM; Locascio JJ; Schlossmacher MG; El-Agnaf OM
    Biochem Biophys Res Commun; 2006 Oct; 349(1):162-6. PubMed ID: 16930553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
    Schell H; Hasegawa T; Neumann M; Kahle PJ
    Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
    Ono K; Yamada M
    Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy.
    Shahnawaz M; Mukherjee A; Pritzkow S; Mendez N; Rabadia P; Liu X; Hu B; Schmeichel A; Singer W; Wu G; Tsai AL; Shirani H; Nilsson KPR; Low PA; Soto C
    Nature; 2020 Feb; 578(7794):273-277. PubMed ID: 32025029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.